Zacks Research Has Negative View of MetaVia FY2026 Earnings

MetaVia Inc. (NASDAQ:MTVA) – Equities researchers at Zacks Research reduced their FY2026 earnings per share estimates for shares of MetaVia in a research note issued on Thursday, May 21st. Zacks Research analyst D. Bautz now expects that the company will earn ($1.87) per share for the year, down from their prior forecast of ($1.86). The consensus estimate for MetaVia’s current full-year earnings is ($2.78) per share.

MetaVia (NASDAQ:MTVA) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03).

A number of other brokerages have also commented on MTVA. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of MetaVia in a report on Monday, May 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a report on Friday, April 24th. Finally, Wall Street Zen raised MetaVia from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $20.00.

MetaVia Price Performance

Shares of NASDAQ MTVA opened at $2.97 on Wednesday. The stock’s fifty day moving average price is $1.56 and its two-hundred day moving average price is $4.11. MetaVia has a one year low of $0.97 and a one year high of $19.03. The firm has a market cap of $15.33 million, a price-to-earnings ratio of -0.57 and a beta of 0.59.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC increased its stake in MetaVia Inc. (NASDAQ:MTVA) by 44.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 60,386 shares of the company’s stock after purchasing an additional 18,506 shares during the period. SG Americas Securities LLC owned approximately 0.25% of MetaVia worth $57,000 as of its most recent filing with the SEC. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.